Last Update 17 Feb 26

Fair value Decreased 10%

MEDP: Higher Margins And Buybacks Will Support Rich Market Expectations

Analysts have trimmed their average price target on Medpace Holdings by about $55 to $490.50 as revised models reflect updated revenue growth assumptions, a slightly different discount rate, higher expected profit margins, and a higher future P/E multiple, informed by a mix of recent upgrades and target changes across the Street.

Analyst Commentary

Recent research has produced a mix of upgrades and target cuts, with Street views clustering around how sustainable Medpace Holdings' growth, margins, and valuation may be after the latest earnings move.

Bullish Takeaways

Bullish analysts upgrading the stock highlight the recent earnings selloff as an entry point, suggesting execution and fundamentals are seen as intact even after short term volatility.
Some recent research raised targets earlier on, pointing to updated models that support a higher P/E multiple, which contributes to the current average target of about US$490.50.
Supportive views generally lean on expectations for higher profit margins embedded in refreshed models, which they see as helping to justify premium valuation versus peers in the contract research space.
Earlier target increases from bullish analysts show that, within the last set of updates, there has been willingness to move estimates higher when underlying assumptions are revised, not just lower them when sentiment cools.

Bearish Takeaways

Bearish analysts trimming targets by amounts such as US$16 and US$78 are signaling that prior revenue and growth expectations may have been too optimistic, pulling back their valuation frameworks accordingly.
Target cuts reflect some caution that even with improved margin assumptions, the stock's P/E and future multiples need to be rebalanced against more measured growth inputs.
Where targets have been reduced, analysts are effectively stressing test cases that assume less generous top line assumptions, which could cap upside if execution does not track those earlier, more optimistic scenarios.
The mix of lower and higher targets within a relatively tight window suggests an active debate on what level of earnings power and growth Medpace can consistently deliver to support current pricing.

What's in the News

Medpace issued full year 2026 guidance, with revenue expected in a range of US$2.755b to US$2.855b on 2025 revenue of US$2.530b, and GAAP net income projected between US$487.0m and US$511.0m, which equates to diluted GAAP EPS of US$16.68 to US$17.50 (company guidance).
The company reported that from October 1, 2025 to December 31, 2025 it repurchased 0 shares for US$0m. It also confirmed that it has completed a total repurchase of 4,498,399 shares for US$1,278.29m under the buyback first announced on October 24, 2022 (company filing).

Valuation Changes

Fair Value: Trimmed from $545.75 to $490.50, a reduction of about 10% in the modeled estimate.
Discount Rate: Adjusted slightly from 7.76% to 7.76%, reflecting a very small change in the rate used to discount future cash flows.
Revenue Growth: Lowered from 12.24% to 9.35%, indicating more measured assumptions for top line expansion in updated models.
Net Profit Margin: Raised from 17.63% to 18.51%, pointing to expectations for somewhat higher profitability on each dollar of revenue.
Future P/E: Increased from 25.55x to 27.07x, suggesting a higher multiple applied to projected earnings in the revised valuation work.

4 views

Key Takeaways

Heavy reliance on faster-burning studies and pass-through revenue may lead to unsustainable growth and margin pressures as project mix normalizes.
Declining backlog, increased competition, and rising operational costs threaten future revenue visibility, profitability, and long-term market share.
Strong industry demand, disciplined capital allocation, and operational excellence position Medpace for sustained, margin-supportive growth despite short-term client and funding challenges.

Catalysts

About Medpace Holdings

Provides clinical research-based drug and medical device development services in North America, Europe, and Asia.What are the underlying business or industry changes driving this perspective?

The rapid revenue acceleration in 2025 is heavily influenced by a therapeutic mix shift toward faster-burning studies (such as metabolic trials) with higher reimbursable costs, increasing "pass-through" revenue that is less margin-accretive, which could result in lower underlying revenue and EBITDA growth once this project mix normalizes.
Funding for many clients, especially small biotech, remains fragile, with low cancellations having driven recent upside; should the improved funding or lower cancellations reverse (as seen in previous quarters), revenue and earnings growth could sharply decelerate, indicating that the current growth levels may not be sustainable.
Despite strong topline growth, win rates for new business were down and backlog is declining (-1.8% year-over-year), suggesting competitive pressures and a lack of large contract wins may negatively impact future bookings and limit revenue and earnings visibility beyond 2025.
The company is guiding for accelerated hiring in the back half of 2025 to support the faster pace of trials, which-combined with higher investigator and salary costs-could increase operating expenses faster than underlying EBITDA if productivity gains plateau or reverse, exerting pressure on net margins.
Biopharma sponsors are increasingly adopting tech-enabled and decentralized trial models, which could enable more internalization of clinical research activities and erode Medpace's market share and pricing power over time, ultimately reducing long-term revenue and margin expansion prospects.

Medpace Holdings Earnings and Revenue Growth

Medpace Holdings Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Medpace Holdings's revenue will grow by 11.8% annually over the next 3 years.
Analysts assume that profit margins will shrink from 18.7% today to 16.9% in 3 years time.
Analysts expect earnings to reach $526.6 million (and earnings per share of $18.07) by about September 2028, up from $418.3 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $471.7 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 21.8x on those 2028 earnings, down from 32.6x today. This future PE is lower than the current PE for the US Life Sciences industry at 29.3x.
Analysts expect the number of shares outstanding to decline by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.21%, as per the Simply Wall St company report.

Medpace Holdings Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Persistent and robust demand for clinical trials-evidenced by strong RFP (Request for Proposal) flow, accelerating backlog conversion, and management's expectations for bookings to return to or exceed historical levels-suggests secular biopharma R&D outsourcing trends remain solid, supporting revenue growth.
Medpace's disciplined capital allocation, demonstrated by significant share repurchases and a large remaining buyback authorization, offers flexibility to enhance earnings per share even in periods of fluctuating business activity, supporting long-term EPS growth potential.
Integrated, full-service operational model and ongoing investment in specialized therapeutic expertise and technology infrastructure are allowing the company to achieve rising productivity, maintain attractiveness for clients, and manage cost efficiency, thereby supporting margins and recurring revenue.
Despite short-term headwinds like cancellations and funding challenges for smaller clients, Medpace's broad backlog, increasing involvement in faster-growing therapeutic areas (such as metabolic studies), and scalable staffing strategy provide resilience and adaptability that favor sustained revenues and margins.
Industry-wide movement towards more complex, tech-enabled, and globalized clinical trials increases demand for CROs with Medpace's capabilities; if these long-term trends continue, Medpace could see continued growth in bookings, revenue, and profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $423.636 for Medpace Holdings based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $510.0, and the most bearish reporting a price target of just $305.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $3.1 billion, earnings will come to $526.6 million, and it would be trading on a PE ratio of 21.8x, assuming you use a discount rate of 7.2%.
Given the current share price of $485.59, the analyst price target of $423.64 is 14.6% lower. Despite analysts expecting the underlying buisness to improve, they seem to believe the market's expectations are too high.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Medpace Holdings?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Future Sector Demand Shifts Will Influence Risk And Reward Dynamics